Aerial view Canary Wharf Lab and Office Spaces for rent
Life Sciences & Health

Canary Wharf: centre of Drug discovery and Precision Medicine in East London

Genetic breakthroughs and innovation at Canary Wharf.

High tech R&D environment

An inspiring environment for Life Sciences and Health innovation

Precision and personalised medicine therapies are already available, such as treatments for some genetic variants of breast cancer or cystic fibrosis, but there is still a lot of research needed to make precision medicine more widely available. Canary Wharf is the epicentre for innovation in the East of London. Much of that research is currently happening at Canary Wharf, where universities, hospitals and industry are leading the way in innovation in precision medicine. 

High tech R&D environment
Canary Wharf London

Highly diverse patient community

At Queen Mary University of London (QMUL) and Barts Cancer Institute, researchers are conducting a large population health study to uncover new disease risk factors. Leveraging genetic and health data from East London’s diverse population, their research aims to improve understanding of genetic links to disease. This data helps distinguish natural genetic variations from disease-causing mutations, advancing personalised medicine. In collaboration with Kings College London and GlaxoSmithKline (GSK), researchers are also exploring why cancer treatment responses vary. Using artificial intelligence to analyse tumour images and biomarker tests, they hope to identify patients at high risk of developing treatment resistance.

One North Quay lab

Well-connected network

Biomarkers present various opportunities for developing new diagnostic tools, often through collaborations between academia, hospitals, and industry. For example, Queen Mary University of London (QMUL) is partnering with Exagen to create personalised diagnostic options for rheumatoid arthritis, focusing on RNA expression patterns to predict treatment response. Precision medicine also relies on new drugs tailored to individual disease variations, making drug discovery increasingly personalised. Biomarkers or gene variants linked to disease can become treatment targets, with new drugs requiring testing in clinical trials designed for specific patient groups. This creates significant opportunities for innovation in precision medicine.

Collaboration

Access to research institutes and regulatory agencies

Companies such as the Medicine & Health Regulatory Authority (MHRA), Genomics England, UCL Management School and the General Pharmaceutical Council are already located at Canary Wharf. A large number of well-cited publications on different aspects of personalised or precision medicine are authored by researchers at institutes in London. Now, a new life sciences research hub in London’s Canary Wharf can open even more opportunities to connect with researchers in the city.

Buildings
2 buildings from Kadans
Local Proximity
128 acres
Location
2.3 million sq ft under construction
Employee
120,000+ employees

Our specialised assets at Canary Wharf

Canary Wharf hosts the London Innovation Centre, offering lab and office spaces for life science companies. Additionally, Kadans Science Partner is developing One North Quay, a health and life sciences building set to open in 2027. This facility will provide space for businesses focused on precision medicine and drug development.

London Innovation Centre

Situated in the renowned ‘Golden Triangle’ of London, Oxford, and Cambridge, the London Innovation Centre serves as a key hub for growing companies in biotechnology and life sciences. The Centre offers flexible, fully serviced lab spaces ranging from 200 sq ft to over 5,000 sq ft, along with office space. Additionally, it features shared lab facilities, allowing start-ups and smaller organisations to lease a single bench until they require larger laboratory space.

Show more
  • CL2 laboratories
  • Shared facilities
  • Meeting rooms
  • Breakout spaces
  • Shared lab spaces
  • Equipment facilities

One North Quay

One North Quay is an upcoming, cutting-edge health and life sciences development located in the heart of Canary Wharf’s Life Sciences district in London. Set to open in 2027, this 23-storey, 823,000 sq ft tower will be Europe’s tallest purpose-built commercial laboratory, featuring high-quality laboratory, manufacturing, and office spaces. One North Quay will be a cornerstone of a vibrant science and technology community, fostering collaboration and innovation in a dynamic urban environment.

Show more
  • Vertical campus
  • 23 storeys
  • Laboratory and offices
  • CL3 wet labs
  • Restaurant present
  • Energy-efficient

Found your perfect space in East London at Canary Wharf? Contact us directly

Call, mail or chat with Oli: +31(0)411 625 625 or o.appleyard@kadans.com

Oli Appleyard

Life Sciences and Health innovation on Canary Wharf

It’s an exciting time for precision medicine, with rapid developments in areas ranging from identifying biomarkers and genetic variants to developing and testing new treatments. And London has proven to be a top location in this field of Life Sciences and Health.

Collaboration
One North Quay lab

Discover your ideal lab space at Kadans

The London Innovation Centre also benefits from access to shared equipment facilities including autoclaves, glass wash, -80 freestanding freezer and on-floor LN2 storage, as well as an in-house Lab Technician to support collaboration and your growth. One North Quay provides high quality laboratory, manufacturing and office accommodation able to accommodate up to  CL3 wet laboratories and GMP manufacturing.

Blauwe moleculen

Discover the world of curing breast cancer with Professor Louise Jones

Discover how Professor Louise Jones and Barts Life Sciences, Barts Health NHS Trust, Queen Mary University of London are separating patient material to change the course of research in their search to cure breast cancer.

“There is nothing so close to the truth as patient material.”
Professor Louise Jones
Barts Cancer Institute
“Cancer treatment is a very significant treatment. You’re giving a woman a diagnosis of cancer when maybe she doesn’t need that diagnosis.”
Professor Louise Jones
Barts Cancer Institute
“We have around 120.000 samples from women with or without breast cancer at different stages. That enables us to ask very specific questions on large cohorts.”
Professor Louise Jones
Barts Cancer Institute
“There is nothing so close to the truth as patient material.”
Professor Louise Jones
Barts Cancer Institute
“Cancer treatment is a very significant treatment. You’re giving a woman a diagnosis of cancer when maybe she doesn’t need that diagnosis.”
Professor Louise Jones
Barts Cancer Institute
“We have around 120.000 samples from women with or without breast cancer at different stages. That enables us to ask very specific questions on large cohorts.”
Professor Louise Jones
Barts Cancer Institute

Are you ready to innovate together?

Oli Appleyard
Oli Appleyard Leasing Manager